Cooley Secures Win for Liquidia to Launch First Product
April 06, 2024
April 06, 2024
WASHINGTON, April 6 -- Cooley, a law firm, issued the following news release:
Cooley successfully overturned a Hatch-Waxman injunction for Liquidia Technologies, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products, enabling Liquidia to launch its new drug, Yutrepia.
On March 28, 2024, the US District Court for the District of Delaware granted Liquidia's Rule 60 motion seeking post-judgment relief to modify p . . .
Cooley successfully overturned a Hatch-Waxman injunction for Liquidia Technologies, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products, enabling Liquidia to launch its new drug, Yutrepia.
On March 28, 2024, the US District Court for the District of Delaware granted Liquidia's Rule 60 motion seeking post-judgment relief to modify p . . .